IN THE CLAIMS

The following listing of claims will replace all prior versions of claims in the application:

- 1. (previously canceled)
- 2. (currently amended) A <u>composition for [method of]</u> treating <u>at least one of virus-induced and inflammatory diseases [of skin and membranes]</u> in [humans or] animals, <u>said composition comprising:</u>

[topical application of a composition comprising]

- at least one of [one or more of the monounsaturated alcohols] octadecenol, eicosenol, docosenol, [and] tetracosenol and hexacosenol [mixed with polar hydrophilic salts in a total concentration] in a concentration of from 0.1 to 25 percent by weight [in] of an admixed [a] physiologically active carrier [to the inflamed skin or membrane of the patient to be treated, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone]:
- at least one salt of a fatty acid according to the formula R¹-COO'M⁺, wherein R¹ comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_x, x is at least one of 6, 8, 10, and 12, and M⁺ is a monovalent alkali metal ion; and
- at least one mixed ester according to the formula R²-COO-R³, wherein R² comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_y, y is at least one of 6, 8, 10 and 12, and R³ is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;
- wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.
- 3. (currently canceled)
- 4. (previously canceled)
- 5. (currently amended) [The method of claim 2 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.] The composition of claim 2,

comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

- 6. (currently cancelled)
- 7. (previously cancelled)
- 8. 9. (currently cancelled)
- 10. (previously cancelled)
- 11. 12. (currently cancelled)
- 13. (previously cancelled)
- 14. (currently amended) A [method of] composition for intravenous treatment of [treating humans or other mammals for] viral infections in animals, said composition comprising:
- [intravenous introduction into the human or other mammal to be treated with] an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound [composition consisting of] comprising [of one or more] at least one C₁₈ to C₂₄ monounsaturated alcohol[s mixed with polar hydrophilic salts in a total concentration] in a physiologically active carrier[, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone];
- at least one salt of a fatty acid according to the formula R¹-COO⁻M⁺, wherein R¹ comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_x, x is at least one of 6, 8, 10, and 12, and M⁺ is a monovalent alkali metal ion; and
- at least one mixed ester according to the formula R²-COO-R³, wherein R² comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_y, y is at least one of 6, 8, 10 and 12, and R³ is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;
- wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.
- 15. (currently cancelled)
- 16. (previously cancelled)

- 17. (currently amended) [The method of claim 14 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.] The composition of claim 14, comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.
- 18. (currently cancelled)
- 19. (previously cancelled)
- 20. (currently amended) A <u>composition for intramuscular treatment of [method of treating humans or other mammals for]</u> viral infections <u>in animals</u>, <u>said composition comprising:</u>
- [intramuscular introduction into the human or other mammal to be treated with] an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound [composition consisting of] comprising [of one or more] at least one C₁₈ to C₂₄ monounsaturated alcohol[s mixed with polar hydrophilic salts in a total concentration] in a physiologically active carrier[, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone];
- at least one salt of a fatty acid according to the formula R¹-COO M⁺, wherein R¹ comprises

 CH3(CH2)7CH=CHCH2(CH2)x, x is at least one of 6, 8, 10, and 12, and M⁺ is a monovalent alkali metal ion; and
- at least one mixed ester according to the formula R²-COO-R³, wherein R² comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_y, y is at least one of 6, 8, 10 and 12, and R³ is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;
- wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.
- 21. (currently cancelled)
- 22. (previously cancelled)
- 23. (currently amended) [The method of claim 20 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.] The composition of claim 20,

comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

- 24. (currently cancelled)
- 25. (previously cancelled)
- 26. (currently amended) A [method of] composition for trans-mucosal treatment of [treating humans or other mammals for] viral infections in animals, said composition comprising:
- [trans-mucus membranal introduction into the human or other mammal to be treated with] an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound [composition consisting of] comprising [of one or more] at least one C₁₈ to C₂₄ monounsaturated alcohol[s mixed with polar hydrophilic salts in a total concentration] in a physiologically active carrier[, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone];
- at least one salt of a fatty acid according to the formula R¹-COO'M⁺, wherein R¹ comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_x, x is at least one of 6, 8, 10, and 12, and M⁺ is a monovalent alkali metal ion; and
- at least one mixed ester according to the formula R²-COO-R³, wherein R² comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_y, y is at least one of 6, 8, 10 and 12, and R³ is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;
- wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.
- 27. (currently cancelled)
- 28. (previously cancelled)
- 29. (currently amended) [The method of claim 26 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, docosenol of about 45%, and tetracosenol of about 9%.] The composition of claim 26, comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

- 30. (currently cancelled)
- 31. (previously cancelled)
- 32. (currently amended) A [method of] composition for transdermal treatment of [treating humans or other mammals for] viral infections in animals, said composition comprising:
- [transdermal penetration into the human or other mammal to be treated with] an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a <u>compound [composition consisting of]</u>

 <u>comprising [of one or more]</u> at least one C₁₈ to C₂₄ monounsaturated alcohol[s mixed with polar hydrophilic salts in a total concentration] in a physiologically active carrier[, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone];
- at least one salt of a fatty acid according to the formula R¹-COO'M⁺, wherein R¹ comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_x, x is at least one of 6, 8, 10, and 12, and M⁺ is a monovalent alkali metal ion; and
- at least one mixed ester according to the formula R²-COO-R³, wherein R² comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_y, y is at least one of 6, 8, 10 and 12, and R³ is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;
- wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.
- 33. (currently cancelled)
- 34. (previously cancelled)
- 35. (currently amended) [The method of claim 32 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicesenol of about 44%, decesenol of about 45%, and tetracosenol of about 9%.] The composition of claim 32, comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

- 36. (currently cancelled)
- 37. 85. (previously cancelled)
- 86. (currently amended) A [method of] composition for trans-membranal treatment of [treating humans and mammals for] viral infections in animals, said composition comprising:
- an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight of a compound comprising [introducing a composition consisting essentially of one or more] at least one monounsaturated alcohol[s] having [from] between 18 [to] and 24 carbons [through a membrane into the circulatory system of a human or mammal to be treated with an effective amount of from about 0.1 mg to about 2 gm per 50 kg of body weight comprising inserting such alcohol composition mixed with polar hydrophilic salts in a total concentration] in at least one of a physiologically acceptable liquid, cream, gel[, or] and suppository carrier into at least one of [the] an anus [or] and vagina of the [human or mammal] animal to be treated[, wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol alone];
- at least one salt of a fatty acid according to the formula R¹-COO'M⁺, wherein R¹ comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_x, x is at least one of 6, 8, 10, and 12, and M⁺ is a monovalent alkali metal ion; and
- at least one mixed ester according to the formula R²-COO-R³, wherein R² comprises

 CH₃(CH₂)₇CH=CHCH₂(CH₂)_y, y is at least one of 6, 8, 10 and 12, and R³ is at least one of an alkyl group and an aliphatic group comprising between 1 to 12 carbon atoms;
- wherein the antiviral activity of the composition is approximately 50 times greater than that of the alcohol component taken alone.
- 87. (currently cancelled)
- 88. (previously cancelled)
- 89. (currently amended) [The method of claim 86 wherein said alcohols are comprised of proportions by weight relative to the total weight of the alcohols of octadecenol of about 1%, eicosenol of about 44%, decesenol of about 45%, and tetracosenol of about 9%.] The composition of claim 86,

comprising at least one of: about 1% octadecenol; about 44% eicosenol; about 45% docosenol; and about 9% tetracosenol by total alcohol weight.

90. (currently cancelled)